A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

New data suggest that olaparib without ADT could be a reasonable treatment strategy in selected patients with high-risk prostate cancer that recurs after radical prostatectomy. Olaparib monotherapy ...

Please provide your email address to receive an email when new articles are posted on . All men with BRCA2 mutations treated with olaparib monotherapy achieved at least a 50% decline in PSA. The study ...

The researchers found 13 participants (26%) had a 50% or higher decline in PSA from baseline (PSA50); all were within the homologous recombination repair-positive group (13 of 27; 48%). (HealthDay ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm ...

The Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in ...

A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib. Objective: To assess the effects of a nurse ...